Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation.
Level 5 - mechanism / opinion, no new human data
In vitro bench study with no human or in vivo data
PubMed 30813369 · doi:10.3390/cells8020194
What was done
The authors evaluated the anti-inflammatory and immunomodulatory mechanisms of sulforaphane (SFN) in lipopolysaccharide (LPS)-activated microglial cells. SFN was tested in pre-treatment and post-treatment protocols under acute and chronic microglial activation conditions. The study assessed MAPK and JNK phosphorylation, downstream NF-κB and AP-1 signaling, pro-inflammatory mediators (iNOS, COX-2, NO, PGE2), pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), anti-inflammatory cytokines (IL-10, IL-4), and Nrf2/HO-1 expression.
What was found
The abstract reports directional findings without specific numerical values, percentages, or statistical effect sizes. SFN pre- and post-treatment significantly reduced MAPK and JNK phosphorylation, which lowered NF-κB and AP-1 signaling. SFN decreased the expression of inflammatory mediators (iNOS, COX-2, NO, PGE2) and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), while increasing Nrf2 and HO-1 expression and IL-10 and IL-4 production.
Why it matters
This study outlines specific biochemical pathways—concurrent JNK/AP-1/NF-κB pathway inhibition and Nrf2/HO-1 activation—involved in sulforaphane's attenuation of neuroinflammatory cascades in vitro.
Limits
This is strictly an in vitro bench experiment; findings cannot establish clinical efficacy, in vivo bioavailability, or blood-brain barrier transport. The abstract provides no quantitative data, sulforaphane dosages, specific microglial cell source details, or sample sizes (replicates).
Cited by
- supports Sulforaphane inhibits the NF-κB inflammatory pathway.